BEAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Beam Therapeutics Inc. (BEAM) presents a strong long-term buy opportunity for a beginner investor with $50,000-$100,000 available. The company has promising catalysts, strong analyst support, and hedge fund interest, despite mixed financial performance and insider selling. The current price level at $24, combined with its long-term growth potential in gene-editing therapies, makes it an attractive entry point.
The MACD is negative but contracting, RSI is neutral at 32.603, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 24.609, with key support at 23.249 and resistance at 25.969. Overall, the technical indicators suggest a neutral to slightly bullish outlook.
Promising early-stage data for BEAM-302 showing significant potential in treating rare liver diseases.
Analysts have consistently raised price targets, with Citi recently setting a target of $
Hedge funds are heavily buying, with a 161.22% increase in buying activity last quarter.
The company is advancing its pipeline with pivotal development for BEAM-302 and a new liver-targeted program, BEAM-304.
Insider selling has surged by 980.39% in the last month, which may indicate caution among internal stakeholders.
Financial performance shows a significant drop in net income (-370.38% YoY) and EPS (-317.43% YoY), despite a strong revenue increase.
In Q4 2025, Beam Therapeutics reported a 279.52% YoY increase in revenue to $114.1M. However, net income dropped significantly by -370.38% YoY to -$244.3M, and EPS declined by -317.43% YoY to -$2.37. Gross margin remained stable at 100%.
Analysts are overwhelmingly positive on BEAM, with multiple firms maintaining Buy ratings and raising price targets. Recent targets range from $26 to $75, with the consensus highlighting the company's strong pipeline and potential for long-term growth.
